<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515993</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1514-QLG-GCG</org_study_id>
    <nct_id>NCT03515993</nct_id>
  </id_info>
  <brief_title>Follow-up in Gynecological Cancer Survivors</brief_title>
  <official_title>Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary&#xD;
      treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to identify physical and psychosocial problems and needs after&#xD;
      treatment for gynecological cancer.&#xD;
&#xD;
      1100 patients stratified by cancer sites and treatment - a minimum of 120 patients within&#xD;
      each stratum - will be recruited.&#xD;
&#xD;
      Institutional data on follow-up policy, demographic and clinical data (related to treatment&#xD;
      history and tumor characteristics) will be collected. Patients will complete a set of 76&#xD;
      Quality of Life questions, at one single time point.&#xD;
&#xD;
      Descriptive analyses will be conducted to characterize the collected data. Multivariate model&#xD;
      building will be used to identify patterns of physical, psychological and social problems&#xD;
      based on factors specific to the patient and to the disease. Logistic multinomial or&#xD;
      continuous regression analysis will be used to investigate which socio-demographic, clinical&#xD;
      variables, or institutional are associated significantly with compromised quality of life and&#xD;
      sexual health outcomes. Exploratory factor analysis will be used to explore the factor&#xD;
      structure of the various PROMs to identify issue clustering.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC QLQ-C30 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered questions on anxiety (from the EORTC quality of life item library)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC OUT-PATSAT-C7 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC Sexual Health Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered Distress Thermometer</description>
  </primary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Gynecologic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Gynecologic cancer patients after primary treatment attending participating hospitals for&#xD;
        routine follow-up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proven gynecological cancer (cervical, endometrial, ovarian (including&#xD;
             fallopian tube and peritoneal primary), vulva).&#xD;
&#xD;
          -  FIGO stage I-IV before completion of primary therapy.&#xD;
&#xD;
          -  Disease-free without any evidence of relapse: no symptoms or signs potentially&#xD;
             indicating recurrent disease (assessed according to standard clinical parameters using&#xD;
             physical and gynecological examination, blood tests, CA 125 (ovarian cancer), or&#xD;
             radiological imaging techniques).&#xD;
&#xD;
          -  At least 6 months but no more than 5 years since completion of primary treatment.&#xD;
&#xD;
          -  Performance status 0, 1 or 2 (WHO scale).&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Ability to understand and fill out questionnaires.&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cancer diagnosis in the past 5 years.&#xD;
&#xD;
          -  Patients participating in interventional clinical studies with Quality of Life as&#xD;
             primary endpoint.&#xD;
&#xD;
          -  Any psychological (including pre-existing psychiatric disorders), familial,&#xD;
             sociological or geographical condition potentially hampering compliance with the study&#xD;
             protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>1514@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Greimel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Vermeij</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Vandecasteele</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chretien (CHC) - CHC MontLegia</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryam Bourhaba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Vermeij</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Schmalz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Meregalli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Greggi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Ferrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulmajeed Dayyat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc - Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL 6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petronella Beatrix Ottevanger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC-Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>NL 3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleonora van Dorst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>PL 80 211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmara Klasa-Mazurkiewicz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Zapardiel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Elena Villafranca Iturre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Perez-Romasanta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals University NHS Foundation Trust - Queen Elizabeth The Queen Mother Hospita</name>
      <address>
        <city>Margate</city>
        <state>Kent</state>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Nordin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital NHS Trust</name>
      <address>
        <city>Cliftonville</city>
        <state>Northampton</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roshan Agarwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azmat Hassan Sadozye</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>long-term survival</keyword>
  <keyword>gynecologic cancer</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

